A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

NCT02116569 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab

Sponsor

Janssen Pharmaceutical K.K.